Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Danny D I'm responding to your post because you've been a great poster here. Folks are going to need your positive outlook. As for me, I've had enough. I've finally had enough of a long history of management talking out of two orifices at the same time. Given the fact the current CEO negotiated a takeover of Breathtec by Nash Pharmaceuticals, while he was the sitting CEO of both companies, was further evidence of more of the same. As it relates to the latest corporate double talk, we need not look any further than the latest prospectus filed October 2, 2019:

Short Form Prospectus - September 30, 2019

In the fourth quarter of 2019, the Company expects to begin cGMP synthesis of NP-135 and initiate additional pre-clinical research. In the first quarter of 2020, the Company expects to seek approval for the IBD or IPF trial in Australia, complete its idiopathic pulmonary fibrosis research, complete pre-clinical studies and publish related research papers with respect to all the Company’s animal in vivo studies and begin the IBD or IPF trial. In
the second quarter of 2020, the Company expects to complete the cGMP synthesis of NP-135 and submit for ethics evaluation the NASH NP-135 and the NP-135 CKD study in Australia, New Zealand and the Ukraine, assuming completion of the Maximum Offering. In the third quarter of 2020, the Company expects to begin the NASH NP135 and the NP-135 CKD study. The Company anticipates receiving data from the IBD or IPF phase II study by the fourth quarter of 2021 and from the NASH and CKD studies by the first quarter of 2022.

Preliminary Short Form Prospectus - July 2, 2019

In the third quarter of 2019, the Company expects to seek approval for the IBD trial in Australia, begin cGMP synthesis of NP-135, complete its idiopathic pulmonary fibrosis research and complete pre-clinical studies and publish related research papers with respect to all the Company’s animal in vivo studies. In the first quarter of 2020, the Company expects to complete the cGMP synthesis of NP-135 and submit for ethics evaluation the NASH
NP-135 and the NP-135 CKD study in Australia, New Zealand and the Ukraine, assuming completion of the Maximum Offering. The Company anticipates receiving data from the IBD phase II study by the third quarter of 2020 and from the NASH and CKD studies by the first quarter of 2021.

A quick review of of the above filings show the timelines start merely one quarter (Q1) apart. From there, the timelines begin to divert dramatically. To which, the anticipated data reports are pushed an additional 4 & 5 Quarters further into the future.

It is my understanding that management contributes the additional 12 to 15 months time frame to - The Company’s primary focus has been raising capital in connection with its prospectus offering - as written in the Monthly Progress Report Oct 2019.

To date, the website Corporate Presentation states - expect data reporting Q3 2020 & Q1 2021. When I look back at all the FN posts I put up with those timelines/milestones in mind, I can't help but think how stupid I was to think times had changed.

If I were new to the Bullrun Capital experience, I'd probably be buying the stock a wheel barrel at a time. However, I'm long in the tooth on the wicked wordsmith this group of insiders are able to conjure up to keep folks on the hook long enough to lure other unsuspecting bait to bite the hook - Bait & Switch Scripts.

I have run out of time, patience, and money to continue supporting these people. I'll accept my losses and move on. That goes for Cannabix as well. Anyone paying attention to the FAIMS angle should see the tech is in deep trouble. It remains pure insanity for Dr. Yost to be appointed at Owlstone Medical without any explanation. It proves you are not respected by management. It remains an insiders only game.

There is no device at Algernon. There never was and that speaks volumes for a company supposedly in the breath analysis business since 2016 - with technical roots dating back to 2014. Managment says F*** U everday in every way. Coupling the reverse split to the upcoming dilution will feel like getting rammed by a Mack Truck. How long does anyone think it'll take for a market value of 100MUSD?

Surely with the insiders dumping/diluting along the way.

That's how long it will be before all longs recover thier losses.

If ever.

It's been one helluva hellish run.

Just 1 opinion.

GL2ALL

/////AMG

Isaiah 40:31 King James Version (KJV)
31 But they that wait upon the Lord shall renew their strength; they shall mount up with wings as eagles; they shall run, and not be weary; and they shall walk, and not faint.